PDE4A and myotonic dystrophy type 2: Roflumilast, a PDE4 inhibitor, demonstrated a modest induction of glucose-dependent insulin release in vitro [21], a delayed progression of diabetes in diabetic mice models via improvement of glycaemic variables and protection of pancreatic islets [22], and a glucose-lowering effect in patients with newly diagnosed DM2 [23].